The impact of bortezomib-based induction in newly diagnosed multiple myeloma with chromosome 1q21 gain.

ABSTRACT:

Introduction

Bortezomib has been reported to favourably impact the outcomes of t(4;14) and del(17p) in multiple myeloma (MM), but its impact on gain 1q (+1q) is unknown.

Methods

To address this, 250 patients treated with bortezomib-based induction were analysed. All myeloma samples had fluorescence in situ hybridization (FISH) performed on CD138-sorted bone marrow aspirate, and plasma cells were analysed using DNA probes specific for the following chromosomal aberrations: del(13q14), del(17p), t(14;16), t(4;14), and +1q. Presence of +1q was defined as the presence of at least three copies of 1q21 at the cut off level of 20% of bone marrow plasma cells.

Results

+1q identified in 167 (66.8%) and associated with t(4;14) and high lactate

SUBMITTER: Tang HKK 

PROVIDER: S-EPMC9019371 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature